Clinical Trials

The Tumor Immunotherapy Program has a number of studies that are currently recruiting patients. For information about how to be referred to one of these studies, please contact us.



Show studies for patients with

Currently Recruiting

  • MERIDIAN

    Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC

    Learn more(opens information in a pop-up overlay)
  • TBI-2001

    Phase I/Ib Study of TBI-2001 for Patients with Relapsed or Refractory CD19+ B-cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

    Learn more(opens information in a pop-up overlay)
  • ADP-0055-001

    A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors

    Learn more(opens information in a pop-up overlay)
  • ADP-0044-002

    A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS)

    Learn more(opens information in a pop-up overlay)
  • IOV-COM-202

    A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144/LN-145/LN-145-S1) in Patients with Solid Tumors

    Learn more(opens information in a pop-up overlay)
  • IOV-LUN-202

    A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

    Learn more(opens information in a pop-up overlay)
  • INSPECT-IO

    Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients

    Learn more(opens information in a pop-up overlay)
  • LANDMARC

    Landscape Mapping of Epitopes and T Cell Receptors for Selected Cancers

    Learn more(opens information in a pop-up overlay)

Recruiting Soon

  • TBio-4101-001

    A Phase 1b Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients with Advanced Solid Tumor Malignancies (STARLING)

    Learn more(opens information in a pop-up overlay)
  • ADP-0055-003

    A Phase 2, Open-Label, Randomized, Non-Comparative Clinical Trial of ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in Subjects With Recurrent Ovarian Cancers

    Learn more(opens information in a pop-up overlay)
  • PANTHEON-IO

    Phase 1 trial of Pantothenic acid in patient with metastatic or unresectable melanoma on Immunotherapy

    Learn more(opens information in a pop-up overlay)
  • TAC01-CLDN18.2-04

    A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects with Unresectable, Locally Advanced or Metastatic Claudin 18.2+ Solid Tumors

    Learn more(opens information in a pop-up overlay)

Closed Recruiting

  • ACTIVATE

    Phase Ib trial of pembrolizumab administered in combination or following adoptive cell therapy: A multiple cohort study

    Learn more(opens information in a pop-up overlay)
  • 1301-02

    Phase 1b Study of NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes in Patients with Solid Tumors

    Learn more(opens information in a pop-up overlay)
  • INSPIRE

    INvestigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation

    Learn more(opens information in a pop-up overlay)
  • METADUR

    An open-label, phase II basket study of a hypomethylating agent azacitidine and durvalumab (anti-PDL1) in advanced solid tumors.

    Learn more(opens information in a pop-up overlay)
  • TILs-003-Meso

    Phase I/II study evaluating the infusion of tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with malignant pleural mesothelioma

    Learn more(opens information in a pop-up overlay)
  • TILs-002-MEL

    Phase II Study Evaluating the Infusion Of Autologous Tumor-Infiltrating Lymphocytes (TILs) And Low-Dose Interleukin-2 (IL-2) Therapy Following A Preparative Regimen Of Non-Myeloablative Lymphodepletion Using Cyclophosphamide And Fludarabine In Patients With Metastatic Melanoma

    Learn more(opens information in a pop-up overlay)
  • TILs-001-DC

    A Phase I Study Evaluating the Feasibility and Safety of Infusion of Re-StimulatedAutologous Tumor-Infiltrating Lymphocytes (TILs) Followed by Low-Dose Interleukin-2 Therapy in Patients with Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Learn more(opens information in a pop-up overlay)
  • MET4-IO

    Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy

    Learn more(opens information in a pop-up overlay)
  • IMCnyeso-101

    A phase I/II study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific soluble T-cell receptor and anti-CD3 bispecific molecule, in HLA-A*0201 positive patients with advanced NY-ESO-1 and/or LAGE - 1A positive cancer

    Learn more(opens information in a pop-up overlay)
  • GSK208750

    Long-Term Follow-Up (LTFU) of Participants Treated with GSK Adoptive Cell Therapies

    Learn more(opens information in a pop-up overlay)
  • SQZ-PBMC-HPV-101

    A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

    Learn more(opens information in a pop-up overlay)
  • CRSP-ONC-003

    A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation

    Learn more(opens information in a pop-up overlay)
  • TCR2-18-01

    A Phase 1/2 Single Arm Open-Label Clinical Trial of Tc-210 T Cells In Patients with Advanced Mesothelin-Expressing Cancer

    Learn more(opens information in a pop-up overlay)